Novel outcome measures for clinical trials in cystic fibrosis

Pediatric Pulmonology

Volumn 50, Issue 3, 2015, Pages 302-315

  Tiddens, Harm A W M ^a   Puderbach, Michael ^b   Venegas, Jose G ^c   Ratjen, Felix ^d   Donaldson, Scott H ^e   Davis, Stephanie D ^f   Rowe, Steven M ^g   Sagel, Scott D ^h   Higgins, Mark ⁱ   Waltz, David A ⁱ  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Hufeland Klinikum Bad Langensalza   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

^h University of Colorado Denver and Children s Hospital Colorado   (United States)

ⁱ VERTEX PHARMACEUTICALS   (United States)

Author keywords

CFTR activity; Cystic fibrosis; Endpoints; Imaging; Outcome measures; Sputum biomarkers

Indexed keywords

BIOLOGICAL MARKER; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE COURSE; GENE MUTATION; HUMAN; INFANT PULMONARY FUNCTION TESTING; LUNG CLEARANCE INDEX; LUNG FUNCTION TEST; MUCOCILIARY CLEARANCE; MULTIPLE BREATH WASHOUT TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPUTUM ANALYSIS; SWEAT TEST; TREATMENT RESPONSE;

EID: 84923201553     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23146     Document Type: Article

References (149)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. 2008 annual data report. Bethesda, Matyland. Last accessed 14 August 2013. http://www.cff.org/treatments/Care- CenterNetwork/PatientRegistryReport/.
2. Ramsey BW. Use of lung imaging studies as outcome measures for development of new therapies in cystic fibrosis. Proc Am Thorac Soc 2007;4:359-363.
3. Yuksel H, Yilmaz O. A new model for cystic fibrosis management: control concept. Pneumologia 2011;60:150-154.
4. Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A, et al. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011;183:752-758.
5. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF,Wainwright CE, Konstan MW, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
6. Davis PB, Yasothan U, Kirkpatrick P. Ivacaftor. Nat Rev Drug Discov 2012;11:349-350.
7. Bakker EM, Borsboom GJ, van der Wiel-Kooij EC, Caudri D, Rosenfeld M, Tiddens HA. Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. Pediatr Pulmonol 2013;48:1081-1088.
8. Bakker M, Borsboom G, Tiddens H. The authors reply. Pediatr Pulmonol 2014;49:1256-1257.
9. Bakker EM, Volpi S, Salonini E, van der Wiel-Kooij EC, Sintnicolaas CJ, Hop WC, Assael BM, Merkus PJ, Tiddens HA. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2011;38:1328-1335.
10. Rosenfeld M, Allen J, Arets BH, Aurora P, Beydon N, Calogero C, Castile RG, Davis SD, Fuchs S, Gappa M, et al. An official American Thoracic Society workshop report: optimal lung function tests for monitoring cystic fibrosis, bronchopulmonary dysplasia, and recurrent wheezing in children less than 6 years of age. Ann Am Thorac Soc 2013;10:S1-S11.
11. Davis SD, Rosenfeld M, Kerby GS, Brumback L, Kloster MH, Acton JD, Colin AA, Conrad CK, Hart MA, Hiatt PW, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med 2010;182:1387-1397.
12. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med 2005;172:1463-1471.
13. Ranganathan SC, Dezateux C, Bush A, Carr SB, Castle RA, Madge S, Price J, Stroobant J, Wade A, Wallis C, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001;358:1964-1965.
14. Hoo AF, Thia LP, Nguyen TT, Bush A, Chudleigh J, Lum S, Ahmed D, Balfour L, Carr I, Chavasse SB, et al. Lung function is abnormal in 3-month-old infants with cystic fibrosis diagnosed by newborn screening. Thorax 2012;67:874-881.
15. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, Robertson CF, Robinson PJ, Franklin PJ, Turner SW, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008;178:1238-1244.
16. Pittman JE, Johnson RC, Davis SD. Improvement in pulmonary function following antibiotics in infants with cystic fibrosis. Pediatr Pulmonol 2012;47:441-446.
17. Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307:2269-2277.
18. The raised volume rapid thoracoabdominal compression technique. The Joint American Thoracic Society/European Respiratory Society Working Group on Infant Lung Function. Am J Respir Crit Care Med 2000;161:1760-1762.
19. Horsley A. Lung clearance index in the assessment of airways disease. Respir Med 2009;103:793-799.
20. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003;22:972-979.
21. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiplebreath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 2008;63:129-134.
22. Ellemunter H, Fuchs SI, Unsinn KM, Freund MC,Waltner-Romen M, Steinkamp G, Gappa M. Sensitivity of Lung Clearance Index and chest computed tomography in early CF lung disease. Respir Med 2010;104:1834-1842.
23. Aurora P, Bush A, Gustafsson P, Oliver C, Wallis C, Price J, Stroobant J, Carr S, Stocks J. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am J Respir Crit Care Med 2005;171:249-256.
24. Lum S, Gustafsson P, Ljungberg H, Hülskamp G, Bush A, Carr SB, Castle R, Hoo AF, Price J, Ranganathan S, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007;62:341-347.
25. Owens CM, Aurora P, Stanojevic S, Bush A, Wade A, Oliver C, Calder A, Price J, Carr SB, Shankar A, et al. Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 2011;66:481-488.
26. Vermeulen F, Proesmans M, Boon M, Havermans T, De Boeck K. Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax 2014;69:39-45.
27. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010;65:379-383.
28. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, Kerrigan S, Gustafsson P, Ratjen F. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011;37:806-812.
29. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD,Weiner DJ, Lee PS, Ratjen F. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med 2013;1:630-638.
30. Fuchs SI, Eder J, Ellemunter H, Gappa M. Lung clearance index: normal values, repeatability, and reproducibility in healthy children and adolescents. Pediatr Pulmonol 2009;44:1180-1185.
31. Fuchs SI, Gappa M. Lung clearance index: clinical and research applications in children. Paediatr Respir Rev 2011;12: 264-270.
32. Fuchs SI, Buess C, Lum S, Kozlowska W, Stocks J, Gappa M. Multiple breath washout with a sidestream ultrasonic flow sensor and mass spectrometry: a comparative study. Pediatr Pulmonol 2006;41:1218-1225.
33. Jensen R, Stanojevic S, Gibney K, Salazar JG, Gustafsson P, Subbarao P, Ratjen F. Multiple breath nitrogen washout: a feasible alternative to mass spectrometry. PLoS ONE 2013;8:e56868.
34. Kent L, Reix P, Innes JA, Zielen S, Le BM Braggion, Lever S, Arets HG, Brownlee K, Bradley JM, Bayfield K, O'Neill K, et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J Cyst Fibros 2014;13:123-138.
35. Subbarao P, Stanojevic S, Brown M, Jensen R, Rosenfeld M, Davis S, Brumback L, Gustafsson P, Ratjen F. Lung clearance index as an outcome measure for clinical trials in young children with cystic fibrosis. Apilot study using inhaled hypertonic saline. Am J Respir Crit Care Med 2013;188:456-460.
36. Daines C, Morgan W. The importance of imaging in cystic fibrosis. Am J Respir Crit Care Med 2011;184:751-752.
37. De Jong PA, Ottink MD, Robben SG, Lequin MH, Hop WC, Hendriks JJ, Pare PD, Tiddens HA. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004;231:434-439.
38. Eichinger M, Puderbach M, Fink C, Gahr J, Ley S, Plathow C, Tuengerthal S, Zuna I, Muller FM, Kauczor HU. Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis-initial results. Eur Radiol 2006;16:2147-2152.
39. Loeve M, van Hal PT, Robinson P, De Jong PA, Lequin MH, Hop WC, Williams TJ, Nossent GD, Tiddens HA. The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease. Thorax 2009;64:876-882.
40. Eichinger M, Optazaite DE, Kopp-Schneider A, Hintze C, Biederer J, Niemann A, Mall MA, Wielputz MO, Kauczor HU, Puderbach M. Morphologic and functional scoring of cystic fibrosis lung disease using MRI. Eur J Radiol 2012;81:1321-1329.
41. Ohno Y, Koyama H, Yoshikawa T, Nishio M, Matsumoto S, Iwasawa T, Sugimura K. Pulmonary magnetic resonance imaging for airway diseases. J Thorac Imaging 2011;26:301-316.
42. Puderbach M, Eichinger M, Haeselbarth J, Ley S, Kopp-Schneider A, Tuengerthal S, Schmaehl A, Fink C, Plathow C, Wiebel M, et al. Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest X-ray. Invest Radiol 2007;42:715-725.
43. Amin R, Charron M, Grinblat L, Shammas A, Grasemann H, Graniel K, Ciet P, Tiddens H, Ratjen F. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. Radiology 2012;264:868-875.
44. Chen DL, Schuster DP. Positron emission tomography with [18F] fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004;286:L834-L840.
45. De Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006;61:80-85.
46. Sly PD, Ware RS, de Klerk N, Stick SM. Randomised controlled trials in cystic fibrosis: what, when and how?. Eur Respir J 2011;37:991-993.
47. Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM. Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 2013;368:1963-1970.
48. Hall GL, Logie KM, Parsons F, Schulzke SM, Nolan G, Murray C, Ranganathan S, Robinson P, Sly PD, Stick SM, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. PLoS ONE 2011;6:e23932.
49. Stick SM, Brennan S, Murray C, Douglas T, von Ungern- Sternberg BS, Garratt LW, Gangell CL, de KN, Linnane B, Ranganathan S, et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr 2009;155:623-628.
50. Mott LS, Park J, Murray CP, Gangell CL, de Klerk NH, Robinson PJ, Robertson CF, Ranganathan SC, Sly PD, Stick SM. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67:509-516.
51. Loeve M, Gerbrands K, Hop WC, Rosenfeld M, Hartmann IC, Tiddens HA. Bronchiectasis and pulmonary exacerbations in children and young adults with cystic fibrosis. Chest 2011;140:178-185.
52. Loeve M, Tiddens H, Gorbunova V, Hop WC, de Bruijne M. Reversibility of trapped air on CT scans of CF patients, an automated approach. Pediatr Pulmonol 2011;46:-359. Abstract 349.
53. Brody AS, Sucharew H, Campbell JD, Millard SP, Molina PL, Klein JS, Quan J. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1128-1132.
54. Loeve M, Hop WC, de Bruijne M, van Hal PT, Robinson P, Aitken ML, Dodd JD, Tiddens HA. Chest computed tomography scores are predictive of survival in patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2012;185:1096-1103.
55. Tepper LA, Utens EM, Caudri D, Bos AC, Gonzalez-Graniel K, Duivenvoorden HJ, van der Wiel EC, Quittner AL, Tiddens HA. Impact of bronchiectasis and trapped air on quality of life and exacerbations in cystic fibrosis. Eur Respir J 2013;42:371-379.
56. Sanders DB, Li Z, Brody A, Farrell PM. Bronchiectasis on chest CT predicts future lung disease severity in children with CF. Pediatr Pulmonol 2011;46(Suppl 34):330. Abstract 327.
57. Eichinger M, Heussel CP, Kauczor HU, Tiddens H, Puderbach M. Computed tomography and magnetic resonance imaging in cystic fibrosis lung disease. J Magn Reson Imaging 2010;32:1370-1378.
58. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007;357:2277-2284.
59. Sanders DB, Li Z, Rock MJ, Brody AS, Farrell PM. The sensitivity of lung disease surrogates in detecting chest CT abnormalities in children with cystic fibrosis. Pediatr Pulmonol 2012;47:567-573.
60. Willemink MJ, De Jong PA. Pediatric chest computed tomography at a radiation dose approaching a chest radiograph. Am J Respir Crit Care Med 2013;188:626-627.
61. Kubo T, Lin PJ, Stiller W, Takahashi M, Kauczor HU, Ohno Y, Hatabu H. Radiation dose reduction in chest CT: a review. AJR Am J Roentgenol 2008;190:335-343.
62. Kalra MK,Woisetschlager M, Dahlstrom N, Singh S, Digumarthy S, Do S, Pien H, Quick P, Schmidt B, Sedlmair M, et al. Sinogram-affirmed iterative reconstruction of low-dose chest CT: effect on image quality and radiation dose. AJR Am J Roentgenol 2013;201:W235-W244.
63. Bang DH, Lim D, Hwang WS, Park SH, Jeong OM, Kang KW, Kang H. Lateral topography for reducing effective dose in low-dose chest CT. AJR Am J Roentgenol 2013;200:1294-1297.
64. Kuo W, Ciet P, Tiddens HA, ZhangW, Guillerman RP, van Straten M. Monitoring cystic fibrosis lung disease by computed tomography. Radiation risk in perspective. Am J Respir Crit Care Med 2014;189:1328-1336.
65. Brody AS, Guillerman RP. Don't let radiation scare trump patient care: 10 ways you can harm your patients by fear of radiation-induced cancer from diagnostic imaging. Thorax 2014;69:782-784.
66. Matsuoka S, Hunsaker AR, Gill RR, Jacobson FL, Ohno Y, Patz S, Hatabu H. Functional MR imaging of the lung. Magn Reson Imaging Clin N Am 2008;16:275-289.
67. Puderbach M, Eichinger M, Gahr J, Ley S, Tuengerthal S, Schmahl A, Fink C, Plathow C, Wiebel M, Muller FM, et al. Proton MRI appearance of cystic fibrosis: comparison to CT. Eur Radiol 2007;17:716-724.
68. Wielpütz MO, Puderbach M, Kopp-Schneider A, Stahl M, Fritzsching E, Sommerburg O, Ley S, Sumkauskaite M, Biederer J, Kauczor HU, et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014;189:956-965.
69. Failo R, Wielopolski PA, Tiddens HA, Hop WC, Mucelli RP, Lequin MH. Lung morphology assessment using MRI: a robust ultra-short TR/TE 2D steady state free precession sequence used in cystic fibrosis patients. Magn Reson Med 2009;61:299-306.
70. th Annual Scientific Assembly and Annual Meeting of the Radiological Society of North America. Chicago, IL, USA, 27 November - 02 December 2011 (Abstract).
71. Puderbach M, Eichinger M. The role of advanced imaging techniques in cystic fibrosis follow-up: is there a place for MRI?. Pediatr Radiol 2010;40:844-849.
72. Redmond A, Sweeney L, MacFarland M, Mitchell M, Daggett S, Kubin R. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning. J Int Med Res 1998;26:304-312.
73. Jannin P, Fitzpatrick JM, Hawkes DJ, Pennec X, Shahidi R, Vannier MW. Validation of medical image processing in image-guided therapy. IEEE Trans Med Imaging 2002;21:1445-1449.
74. MacKenzie JD, Vasanawala SS. Advances in pediatric MR imaging. Magn Reson Imaging Clin N Am 2008;16:385-402.
75. Fain SB, Korosec FR, Holmes JH, O'Halloran R, Sorkness RL, Grist TM. Functional lung imaging using hyperpolarized gas MRI. J Magn Reson Imaging 2007;25:910-923.
76. 2 enhanced MRI of the pathologic lung: findings in emphysema, fibrosis, and cystic fibrosis. Int J Biomed Imaging 2007;2007:23624.
77. Sun Y, O'Sullivan BP, Roche JP, Walvick R, Reno A, Baker D, Mansour JK, Albert MS. Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patients. J Magn Reson Imaging 2011;34:1206-1211.
78. Bauman G, Puderbach M, Deimling M, Jellus V, Chefd'hotel C, Dinkel J, Hintze C, Kauczor HU, Schad LR. Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of fourier decomposition in proton MRI. Magn Reson Med 2009;62:656-664.
79. Chen DL, Kinahan PE. Multimodality molecular imaging of the lung. J Magn Reson Imaging 2010;32:1409-1420.
80. Harris RS, Venegas JG, Wongviriyawong C, Winkler T, Kone M, Musch G, Vidal Melo, de Prost MF, Hamilos N, Afshar DL, et al. 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma. J Nucl Med 2011;52:1713-1720.
81. Dolovich MB, Schuster DP. Positron emission tomography and computed tomography versus positron emission tomography computed tomography: tools for imaging the lung. Proc Am Thorac Soc 2007;4:328-333.
82. Labiris NR, Nahmias C, Freitag AP, Thompson ML, Dolovich MB. Uptake of 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation?. Eur Respir J 2003;21:848-854.
83. Klein M, Cohen-Cymberknoh M, Armoni S, Shoseyov D, Chisin R, Orevi M, Freedman N, Kerem E. F-fluorodeoxyglucose-PET/CT imaging of lungs in patients with cystic fibrosis. Chest 2009;136:1220-1228.
84. Musch G, Venegas JG. Positron emission tomography imaging of regional lung function. Minerva Anestesiol 2006;72:363-367.
85. Schroeder T, Vidal Melo MF, Musch G, Harris RS, Winkler T, Venegas JG. PET imaging of regionalF-FDG uptake and lung function after cigarette smoke inhalation. J Nucl Med 2007; 48:413-419.
86. Musch G, Winkler T, Harris RS, Vidal Melo MF, Wellman TJ, de Prost N, Kradin RL, Venegas JG. Lung [F]fluorodeoxyglucose uptake and ventilation-perfusion mismatch in the early stage of experimental acute smoke inhalation. Anesthesiology 2014;120:683-693.
87. Laube BL, Sharpless G, Carson KA, Kelly A, Mogayzel PJ, Jr. Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis. BMC Pulm Med 2011;11:45.
88. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-250.
89. Lindström M, Camner P, Falk R, Hjelte L, Philipson K, Svartengren M. Long-term clearance from small airways in patients with cystic fibrosis. Eur Respir J 2005;25:317-323.
90. Robinson M, Eberl S, Tomlinson C, Daviskas E, Regnis JA, Bailey DL, Torzillo PJ, Menache M, Bye PT. Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med 2000;13:73-86.
91. Donaldson SH, Corcoran TE, Laube BL, Bennett WD. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 2007;4:399-405.
92. Laube BL, Auci RM, Shields DE, Christiansen DH, Lucas MK, Fuchs HJ, Rosenstein BJ. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.Am J Respir Crit Care Med 1996;153:752-760.
93. Robinson M, Hemming AL, Moriarty C, Eberl S, Bye PT. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis. Pediatr Pulmonol 2000;30: 16-24.
94. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014;190:175-184.
95. Bennett WD, Laube BL, Corcoran T, Zeman K, Sharpless G, Thomas K, Wu J, Mogayzel PJ, Jr., Pilewski J, Donaldson S. Multisite comparison of mucociliary and cough clearance measures using standardized methods. J Aerosol Med Pulm Drug Deliv 2013;26:157-164.
96. Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD. Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset. Expert Rev Mol Diagn 2011;11:197-206.
97. Sagel SD, Chmiel JF, Konstan MW. Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 2007;4:406-417.
98. Al-Saleh S, Dell SD, Grasemann H, Yau YC, Waters V, Martin S, Ratjen F. Sputum induction in routine clinical care of children with cystic fibrosis. J Pediatr 2010;157:1006-1011.
99. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, Sagel SD, Ramsey BW. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am J Respir Crit Care Med 2007;175:822-828.
100. Ordoñez CL, Kartashov AI, Wohl ME. Variability of markers of inflammation and infection in induced sputum in children with cystic fibrosis. J Pediatr 2004;145:689-692.
101. Reinhardt N, Chen CI, Loppow D, Schink T, Kleinau I, Jörres RA, Wahn U, Magnussen H, Paul KP. Cellular profiles of induced sputum in children with stable cystic fibrosis: comparison with BAL. Eur Respir J 2003;22:497-502.
102. Smountas AA, Lands LC, Mohammed SR, Grey V. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers. Clin Biochem 2004;37:1031-1036.
103. Liou TG, Adler FR, Keogh RH, Li Y, Jensen JL, Walsh W, Packer K, Clark T, Carveth H, Chen J, et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS ONE 2012;7:e42748.
104. Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186:857-865.
105. Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, Cariani L, Daccò V, Prato R, Conese M. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. Int J Immunopathol Pharmacol 2011;24:423-432.
106. Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch- Bogart GZ, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475.
107. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
108. Chmiel JF, Konstan MW, Lymp J, Mayer-Hamblett N, Hilliard KA, Accurso FJ, Ramsey B. Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF. Pediatr Pulmonol 2014;42(S30):228. Abstract.
109. Laguna TA, Wagner BD, Luckey HK, Mann SA, Sagel SD, Regelmann W, Accurso FJ. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis. Chest 2009;136:1561-1568.
110. Porro C, Lepore S, Trotta T, Castellani S, Ratclif L, Battaglino A, Di Gioia S, Martinez MC, Conese M, Maffione AB. Isolation and characterization of microparticles in sputum from cystic fibrosis patients. Respir Res 2010;11:94.
111. Hector A, Kormann MS, Mack I, Latzin P, Casaulta C, Kieninger E, Zhou Z, Yildirim AÖ, Bohla A, Rieber N, et al. The chitinase-like protein YKL-40 modulates cystic fibrosis lung disease. PLoS ONE 2011;6:e24399.
112. Fantino E, Gangell CL, Hartl D, Sly PD. Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med 2014;14:28.
113. Reeves EP, Bergin DA, Fitzgerald S, Hayes E, Keenan J, Henry M, Meleady P, Vega-Carrascal I, Murray MA, Low TB, et al. A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis. J Cyst Fibros 2012;11:100-107.
114. Quon BS, Ngan DA,Wilcox PG, Man SF, Sin DD. Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis. PLoS ONE 2014;9:e89341.
115. Wojewodka G, De Sanctis JB, Bernier J, Berube J, Ahlgren HG, Gruber J, Landry J, Lands LC, Nguyen D, Rousseau S, et al. Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients. PLoS ONE 2014;9:e88567.
116. Shoki AH, Mayer-Hamblett N, Wilcox PG, Sin DD, Quon BS. Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. Chest 2013;144:1659-1670.
117. Ratjen F, Saiman L, Mayer-Hamblett N, Lands LC, Kloster M, Thompson V, Emmett P, Marshall B, Accurso F, Sagel S, Anstead M. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-1266.
118. Grob NM, Aytekin M, Dweik RA. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J Breath Res 2008;2:037004.
119. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352:1992-2001.
120. Wilschanski M, Dupuis A, Ellis L, Jarvi K, Zielenski J, Tullis E, Martin S, Corey M, Tsui LC, Durie P. Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med 2006;174:787-794.
121. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. Effect of VX-770 in persons with cystic fibrosis and the G551DCFTR mutation. N Engl J Med 2010;363:1991-2003.
122. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012;67:12-18.
123. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008;372:719-727.
124. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-1441.
125. Mayell SJ, Munck A, Craig JV, Sermet I, Brownlee KG, Schwarz MJ, Castellani C, Southern KW. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009;8:71-78.
126. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-595.
127. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.
128. Naehrlich L, Ballmann M, Davies J, Derichs N, Gonska T, Hjelte L, van Konigsbruggen-Rietschel S, Leal T, Melotti P, et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. J Cyst Fibros 2014;13:24-28.
129. Rowe SM, Clancy JP, Wilschanski M. Nasal potential difference measurements to assess CFTR ion channel activity. Methods Mol Biol 2011;741:69-86.
130. Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet- Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, et al. An international randomized multicenter comparison of nasal potential difference techniques. Chest 2010;138:919-928.
131. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007;37:57-66.
132. Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordo~nez CL, Stone AJ, et al. Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551DCFTR mutation. PLoS ONE 2013;8:e66955.
133. Davies JC, Davies M, McShane D, Smith S, Chadwick S, Jaffe A, Farley R, Collins L, Bush A, Scallon M, et al. Potential difference measurements in the lower airway of children with and without cystic fibrosis. Am J Respir Crit Care Med 2005;171:1015-1019.
134. Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 2013;144:498-506.
135. Cohen-Cymberknoh M, Yaakov Y, Shoseyov D, Shteyer E, Schachar E, Rivlin J, Bentur L, Picard E,Aviram M, Israeli E, et al. Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. Pediatr Pulmonol 2013;48:229-235.
136. De Boeck K, Derichs N, Fajac I, de Jonge HR, Bronsveld I, Sermet I, Vermeulen F, Sheppard DN, Cuppens H, Hug M, et al. New clinical diagnostic procedures for cystic fibrosis in Europe. J Cyst Fibros 2011;10:S53-S66.
137. Derichs N, Sanz J, Von Kanel T, Stolpe C, Zapf A, Tummler B, Gallati S, Ballmann M. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010;65:594-599.
138. Hug MJ, Tümmler B. Intestinal current measurements to diagnose cystic fibrosis. J Cyst Fibros 2004;3:157-158.
139. Mall M, Hirtz S, Gonska T, Kunzelmann K. Assessment of CFTR function in rectal biopsies for the diagnosis of cystic fibrosis. J Cyst Fibros 2004;3:165-169.
140. Mall M, Kreda SM, Mengos A, Jensen TJ, Hirtz S, Seydewitz HH, Yankaskas J, Kunzelmann K, Riordan JR, Boucher RC. The DeltaF508 mutation results in loss of CFTR function and mature protein in native human colon. Gastroenterology 2004;126:32-41.
141. Hirtz S, Gonska T, Seydewitz HH, Thomas J, Greiner P, Kuehr J, Brandis M, Eichler I, Rocha H, Lopes AI, et al. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004;127:1085-1095.
142. Clancy JP, Szczesniak RD, Ashlock MA, Ernst SE, Fan L, Hornick DB, Karp PH, Khan U, Lymp J, Ostmann AJ, et al. Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function. PLoS ONE 2013;8: e73905.
143. Rowe SM, Accurso F, Clancy JP. Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc 2007;4:387-398.
144. Durmowicz AG,Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013;143:14-18.
145. Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E, Conrad D, Shamsuddin AK, Durie P, Gonska T. b-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med 2012;186:732-739.
146. Mattar AC, Leone C, Rodrigues JC, Adde FV. Sweat conductivity: an accurate diagnostic test for cystic fibrosis?. J Cyst Fibros 2014;13:528-533.
147. Flume PA, Liou TG, Borowitz DS, Li H, Yen K, Ordoñez CL, Geller DE. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142: 718-724.
148. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 2013;187:1219-1225.
149. Wine JJ, Char JE, Chen J, Cho HJ, Dunn C, Frisbee E, Joo NS, Milla C, Modlin SE, Park IH, et al. In vivo readout of CFTR function: ratiometric measurement of CFTR-dependent secretion by individual, identifiable human sweat glands. PLoS ONE 2013;8:e77114.